Status:
COMPLETED
Aldesleukin in Participants With Metastatic Renal Cell Carcinoma or Metastatic Melanoma
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Metastatic Renal Cell Carcinoma
Metastatic Melanoma
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
This study evaluated the pharmacokinetics of aldesleukin in participants with metastatic renal cell cancer or metastatic melanoma.
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Performance Status Eastern Cooperative Oncology Group: 0 or 1.
- Adequate organ function.
- Exclusion criteria:
- Pregnancy or lactation.
- Prior treatment with any form of IL-2.
- Organ transplant. Other protocol-defined inclusion/exclusion criteria may apply
Exclusion
Key Trial Info
Start Date :
September 3 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 28 2010
Estimated Enrollment :
26 Patients enrolled
Trial Details
Trial ID
NCT00414765
Start Date
September 3 2008
End Date
March 28 2010
Last Update
June 8 2021
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
USC/Kenneth Norris Comprehensive Cancer Center
Los Angeles, California, United States, 90033
2
University of Colorado Cancer Center
Aurora, Colorado, United States, 80045
3
James Graham Brown Cancer Center
Louisville, Kentucky, United States, 40202
4
Dartmouth Hitchcock Medical Center
Lebanon, New Hampshire, United States, 03756